Opus Genetics initiated with a Buy at BTIG

BTIG analyst Thomas Shrader initiated coverage of Opus Genetics (IRD) with a Buy rating and $7 price target Opus is a developmental stage biotechnology company focused on gene therapy approaches to treat and correct inherited retinal disease, the analyst tells investors in a research note. The firm says the company has “cherry-picked indications where the biology is well validated.” Opus’ two key programs should provide steady news flow beginning in Q1 with Phase 1 data that “could be highly de-risking” in BEST1 disease, contends BTIG.